CETP -629C>A

CETP -629C>A — The HDL Promoter Switch

Every day your liver makes a protein called CETP | Cholesteryl Ester Transfer
Protein — an enzyme that shuttles cholesteryl esters from protective HDL particles
to LDL and VLDL, effectively draining your HDL of its cargo.
The more CETP your liver produces, the lower your HDL cholesterol tends to be.
A single nucleotide change in the CETP gene's promoter region — 629 bases
upstream of the transcription start site — determines how much CETP your liver
produces, and therefore shapes your HDL cholesterol set point from birth.

The Mechanism

The -629 position sits within a Sp1/Sp3 transcription factor binding site | Sp1
and Sp3 are zinc-finger proteins that bind GC-rich DNA sequences and regulate
transcription — Sp3 commonly acts as a repressor when it outcompetes Sp1 at the
same site. The C allele creates a
sequence that Sp1 and Sp3 bind poorly. The A allele creates a high-affinity Sp1/Sp3
binding site — and Sp3 at this position acts as a transcriptional repressor,
suppressing CETP gene expression by approximately 25%.

Carriers of the A allele therefore have lower circulating CETP protein. Because
CETP transfers cholesteryl esters from HDL to LDL and VLDL, less CETP activity
means cholesteryl esters accumulate inside HDL particles — raising measured HDL
cholesterol. The original mechanistic study by Dachet et al.
showed that CC homozygotes had 0.45 μg/mL higher circulating CETP mass than
AA homozygotes, and correspondingly lower HDL-C levels, in 536 subjects from
the ECTIM study.

The Evidence

The largest and most rigorous study of this variant is the Women's Genome Health
Study (WGHS) | Ridker et al. 2009; 18,245 initially healthy American women of
European ancestry, followed prospectively for ~10 years for cardiovascular
events. In this genome-wide analysis,
rs1800775 was identified as the single most strongly associated SNP in the entire
CETP region for HDL-C. HDL-C was approximately 52 mg/dL in CC carriers, 52 mg/dL
in CA carriers, and 54 mg/dL in AA homozygotes. The age-adjusted hazard ratio for
myocardial infarction was 0.82 per A allele (P=0.048), though this association
was attenuated when HDL-C was included in the model (HR 0.90, P=0.31) — suggesting
the cardiovascular effect operates largely through HDL.

A 2015 resequencing study | Pirim et al. Metabolism 2015; 602 non-Hispanic
whites and 353 African blacks confirmed
that rs1800775 independently associates with HDL-C in both European and African
populations. Importantly, in Europeans this variant is in strong LD with TaqIB
(rs708272, r²=0.75), but in African Americans LD is much weaker (r²=0.19) —
meaning rs1800775 and TaqIB may capture largely overlapping signals in Europeans
but distinct functional variation in Africans.

A meta-analytic evaluation
of 17 studies (5,441 CHD cases, 7,967 controls, 22,488 subjects in lipid analyses)
found that the C allele associates with 3.65–4.36 mg/dL lower HDL-C and 0.45
μg/mL higher CETP mass. Among Caucasian populations, CC carriers had significantly
higher CHD odds (OR 1.41–1.43 under dominant/homozygous models), while overall
association in mixed populations was not significant — consistent with population
heterogeneity in LD structure.

The HDL-C Paradox

A critical nuance: CETP variants that raise HDL by reducing cholesteryl ester
transfer do not always translate into the same cardiovascular protection as HDL
raised by other means. The HDL-raising effect of the -629A allele is partly
attenuated by elevated triglycerides | When TG-rich lipoproteins are high, CETP
transfer activity from HDL becomes dominated by mass-action effects of the TG
substrate; CETP genotype effects on HDL diminish in high-TG states.
The interaction between CETP genotype and plasma triglycerides means that the
-629A benefit on HDL is largest at low triglyceride levels.

Practical Actions

For CC homozygotes, CETP expression is at its highest reference level, and HDL-C
tends to run 3–6 mg/dL lower than in AA homozygotes. This is a modest but
consistent effect operating as a background risk factor for low HDL.
Lifestyle-level intervention can offset the genotype: aerobic exercise is one of
the most robust HDL-raising stimuli and works regardless of CETP genotype.
Dietary fat quality (replacing saturated fat with unsaturated fat) also supports
HDL levels. The clinical priority for CC individuals is ensuring HDL-C is
monitored regularly and that other lipid risk factors (LDL, triglycerides) are
well managed, since the genotype alone does not cause disease.

For CA heterozygotes, HDL-C is in the population range but slightly elevated
relative to CC individuals. No specific intervention is required.

For AA homozygotes, lower CETP activity raises HDL-C. Monitoring the full lipid
panel rather than HDL alone is worthwhile: if HDL is elevated alongside high
triglycerides, the cardiovascular benefit is reduced.

Interactions

rs1800775 is in strong LD with the CETP TaqIB variant rs708272 in European
populations (r²=0.75). Tests that report TaqIB are largely capturing the same
signal in Europeans, though rs1800775 is considered the functional variant given
its direct transcriptional effect. In African ancestry populations, the two SNPs
are only weakly correlated (r²=0.19), and both should be assessed independently.

CETP variants interact additively with LIPC variants (rs1532085) in raising
HDL-C, but studies suggest the CETP-side interaction is what primarily translates
to cardiovascular benefit. For individuals carrying CETP CC and LIPC GG genotypes,
HDL may be at its lowest for both loci and monitoring is most important.